SynthesisFrontiers in pharmacology2026
Protective effects and possible mechanisms of matrine-type alkaloids (matrine and oxymatrine) in animal models of ulcerative colitis: a preclinical systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Matrine and oxymatrine are bioactive alkaloids from Sophora species with reported anti-inflammatory and antioxidant effects in ulcerative colitis (UC). However, their overall efficacy has not been systematically evaluated. Methods: Databases including PubMed, EMBASE, Web of Science, Scopus, CNKI, Wanfang, VIP, and SinoMed were searched to January 2026. Animal studies using matrine or oxymatrine monotherapy in UC models were included. Effect sizes were calculated as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Results: Thirteen studies were included. Compared with controls, matrine-type alkaloids significantly reduced histopathological scores (SMD = -3.47, 95% CI: -4.83 to -2.11) and decreased Disease Activity Index (DAI) at 3 days (SMD = -2.92, 95% CI: -4.27 to -1.57) and 7 days (SMD = -4.76, 95% CI: -6.30 to -3.23), but not at 14 days (SMD = -1.01, 95% CI: -2.22 to 0.20). Body weight increased at 7 days (SMD = 2.76, 95% CI: 1.95-3.57) and 14 days (SMD = 2.41, 95% CI: 0.12-4.69), and colon length was also increased (SMD = 2.09, 95% CI: 1.55-2.64). Matrine-type alkaloids reduced TNF-α (SMD = -2.88, 95% CI: -3.50 to -2.26), IL-6 (SMD = -2.91, 95% CI: -4.64 to -1.17), IL-1β (SMD = -2.73, 95% CI: -4.27 to -1.19), and MDA levels (SMD = -3.06, 95% CI: -4.47 to -1.65), while increasing SOD activity (SMD = 2.63, 95% CI: 1.37-3.89). Subgroup analyses suggested generally similar directions of effect across species and model types. The pooled effect estimate appeared larger in the oxymatrine subgroup than in the matrine subgroup, but this indirect comparison should be interpreted cautiously. Conclusion: Matrine-type alkaloids may exert protective effects in UC animal models by improving histological damage, reducing disease activity, and modulating inflammatory and oxidative stress pathways. These findings suggest their potential as multi-target therapeutic agents, although further high-quality studies are required for clinical translation. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261376235, identifier CRD420261376235.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.